Dydrogesterone (Duphaston): The Complete HRT Guide

Quick Reference Card

Overview / What Is Dydrogesterone?

The Basics

Dydrogesterone is a type of progestogen, a class of hormones that protect the uterine lining when you take estrogen as part of hormone replacement therapy. If you have your uterus and take estrogen without a progestogen, the lining can overgrow and potentially become cancerous. Dydrogesterone prevents this.

What makes dydrogesterone different from many other progestogens is how closely it resembles the progesterone your body makes naturally. It is a mirror-image version (a stereoisomer) of natural progesterone, with a slightly altered molecular shape that gives it some practical advantages: it works well when taken by mouth, and it is highly selective for the progesterone receptor without triggering other hormone receptors that can cause unwanted side effects like acne, weight gain, or mood changes [1][2].

Dydrogesterone was first developed in the 1950s and has been prescribed in over 100 countries for more than 60 years [2]. It is best known by the brand name Duphaston (as a standalone product) and Femoston (in combination with estradiol for HRT). One important distinction: dydrogesterone is not available in the United States. It has never been submitted for FDA approval, which means that most North American prescribers are less familiar with it. In Europe, the UK, Australia, and much of Asia, however, it is widely used and well-established.

Beyond HRT, dydrogesterone is also prescribed for menstrual disorders, endometriosis, premenstrual syndrome, and as luteal phase support in fertility treatments [2]. This guide focuses specifically on its role in menopausal hormone therapy.

The Science

Dydrogesterone (6-dehydro-retroprogesterone; C21H28O2; molecular weight 312.45 g/mol) is a retroprogesterone, a class of synthetic progestogens characterized by a spatial configuration that is the reverse of natural progesterone. Specifically, the methyl group at carbon 10 is in the alpha-orientation (rather than beta), and the hydrogen at carbon 9 is in the beta-orientation (rather than alpha). An additional double bond exists between carbons 6 and 7 [1][2].

These structural modifications create a "bent" molecular conformation that confers high selectivity for the progesterone receptor (PR). In vitro receptor binding studies demonstrate that dydrogesterone and its primary active metabolite, 20-alpha-dihydrodydrogesterone (DHD), activate PR-mediated transcription without clinically relevant agonistic or antagonistic activity at androgen, estrogen, glucocorticoid, or mineralocorticoid receptors [1][2][3]. This selective receptor profile distinguishes dydrogesterone from progestins derived from 19-nortestosterone (such as norethindrone and levonorgestrel) and from some pregnane derivatives (such as medroxyprogesterone acetate), which exhibit varying degrees of androgenic, glucocorticoid, or antimineralocorticoid cross-reactivity [3].

Dydrogesterone's oral bioavailability is approximately 28%, which is substantially higher than that of micronized progesterone (approximately 15-20%) [1]. This higher bioavailability, combined with its potent progestogenic activity, allows therapeutic effect at doses 10 to 20 times lower than micronized progesterone (10 mg dydrogesterone providing endometrial transformation comparable to 200 mg micronized progesterone) [2][3].

Clinically, dydrogesterone has been commercially available since the 1960s. It is approved in over 100 countries and is classified under ATC code G03FA14 (in combination with estradiol) and G03DB01 (standalone) [1][2].

Medical / Chemical Identity

Generic Name: Dydrogesterone

Chemical Name: 6-Dehydro-9beta,10alpha-progesterone; (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one

Molecular Formula: C21H28O2

Molecular Weight: 312.45 g/mol

CAS Number: 152-62-5

Drug Class: Retroprogesterone (synthetic progestogen)

Regulatory Status:

Brand Names:

Marketing Authorization (UK): PL 44081/0035 (Femoston-conti 0.5/2.5), first authorized 28/05/2010

Mechanism of Action

The Basics

Dydrogesterone works by binding to progesterone receptors in the uterine lining and transforming it from a growth phase to a stable, organized state. This is the fundamental reason any progestogen is added to estrogen therapy when you have your uterus: to prevent the lining from overgrowning in response to estrogen.

What sets dydrogesterone apart is what it does not do. Unlike some other progestogens, it does not activate androgen receptors (which can cause acne, oily skin, or hair loss), does not activate glucocorticoid receptors (which can affect metabolism and mood), and does not stimulate or block mineralocorticoid receptors (which regulate fluid balance) [1][2]. Think of it as a very targeted messenger: it delivers its message to the progesterone receptor and mostly leaves other systems undisturbed.

One notable difference from micronized progesterone is that dydrogesterone does not produce the sleep-promoting metabolite allopregnanolone. Micronized progesterone, when taken orally, gets converted in the liver to this compound, which has calming and sedating effects through the brain's GABA system [4]. Dydrogesterone bypasses this pathway entirely. For some women, this is an advantage because they avoid daytime drowsiness. For others who rely on their evening progesterone to help them sleep, this may be a trade-off.

Dydrogesterone also plays a role in immune modulation by promoting the production of progesterone-induced blocking factor (PIBF), which helps create a tolerant immune environment. This is why it is also used extensively in fertility medicine and early pregnancy support [2].

The Science

Dydrogesterone binds selectively to intracellular progesterone receptors (PR-A and PR-B), initiating the classical genomic signaling pathway: ligand-receptor binding, dimerization, nuclear translocation, and binding to progesterone response elements (PREs) in target gene promoters. In the endometrium, this activates secretory transformation genes, downregulates estrogen receptor expression, and induces local 17-beta-hydroxysteroid dehydrogenase activity, collectively opposing estrogen-driven proliferation [1][2].

The selectivity of dydrogesterone for the PR has been confirmed by Rizner et al. (2011), who demonstrated that dydrogesterone and 20-alpha-dihydrodydrogesterone (DHD) exhibit potent progestogenic activity with no or negligible agonistic activity at androgen receptors (AR), estrogen receptors (ER-alpha, ER-beta), glucocorticoid receptors (GR), or mineralocorticoid receptors (MR) [3]. This receptor selectivity profile is pharmacologically distinct from medroxyprogesterone acetate (which has glucocorticoid and weak androgenic activity), norethindrone acetate (androgenic activity), and even micronized progesterone (which has antimineralocorticoid and, through allopregnanolone, GABAergic activity) [3].

A distinguishing pharmacological feature is the retention of the 4,6-diene-3-one configuration in all metabolites of dydrogesterone, which accounts for the absence of 17-alpha-hydroxylation and the resulting lack of estrogenic and androgenic metabolites [1]. This is in contrast to some 19-nortestosterone-derived progestins that generate androgenic metabolites during hepatic metabolism.

Dydrogesterone promotes the expression of progesterone-induced blocking factor (PIBF), a 34-kDa protein that modulates the maternal immune response by shifting the Th1/Th2 cytokine balance toward Th2 dominance, suppressing NK cell cytotoxicity through inhibition of perforin release [2]. This immunomodulatory mechanism is the pharmacological basis for its use in threatened miscarriage and recurrent pregnancy loss, though this application falls outside the scope of this HRT guide.

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

When you take dydrogesterone by mouth, it is rapidly absorbed and quickly converted in your body to its main active metabolite, called DHD (20-alpha-dihydrodydrogesterone). In fact, DHD reaches much higher blood levels than dydrogesterone itself, about 25 times the peak concentration, and it is DHD that provides most of the ongoing progestogenic effect [1].

This rapid metabolism means dydrogesterone has a relatively short life in your system. The parent compound clears within 5 to 7 hours, while DHD lasts longer at 14 to 17 hours [1]. This is an important practical point: consistent daily dosing matters, because the drug does not accumulate the way some longer-acting progestogens do. Steady-state blood levels are typically reached within 3 days of starting daily treatment [1].

One advantage of dydrogesterone is its higher oral bioavailability compared to micronized progesterone (about 28% vs 15-20%). This means a larger proportion of each dose actually reaches your system, which is why effective doses of dydrogesterone (2.5-10 mg) are much smaller than those of micronized progesterone (100-200 mg) [1][2].

Dydrogesterone is only available as an oral formulation. There are no transdermal patches, vaginal products, or injectable forms.

The Science

Absorption:
Following oral administration, dydrogesterone is rapidly absorbed with a Tmax of 0.5-2.5 hours. The absolute bioavailability is 28% (established by comparison of oral 20 mg with 7.8 mg intravenous infusion) [1].

Distribution:
The steady-state volume of distribution is approximately 1400 L following intravenous administration. Both dydrogesterone and DHD are greater than 90% bound to plasma proteins [1].

Metabolism:
Dydrogesterone is rapidly and extensively metabolized to 20-alpha-dihydrodydrogesterone (DHD), the principal active metabolite. DHD plasma levels are substantially higher than those of the parent compound, with AUC and Cmax ratios of DHD to dydrogesterone of approximately 40:1 and 25:1, respectively [1]. Mean terminal half-lives are 5-7 hours for dydrogesterone and 14-17 hours for DHD [1][2].

A pharmacologically significant feature is the retention of the 4,6-diene-3-one configuration in all characterized metabolites, which accounts for the absence of 17-alpha-hydroxylation and consequently the lack of estrogenic and androgenic metabolic products [1].

Elimination:
Following oral administration of radiolabeled dydrogesterone, approximately 63% of the dose is excreted in urine, predominantly as DHD glucuronide conjugates. Total plasma clearance is 6.4 L/min. Complete excretion occurs within 72 hours [1].

Dose linearity:
Single- and multiple-dose pharmacokinetics are linear across the oral dose range of 2.5-10 mg. Pharmacokinetics are not altered by repeated dosing. Steady state is achieved after 3 days of treatment [1].

Steady-state PK Parameters (Femoston-conti 0.5/2.5):

Understanding how your body absorbs and metabolizes hormones is one thing. Tracking your actual protocol, doses, timing, and route, gives you the data to have more productive conversations with your prescriber. Doserly lets you log every dose with route-specific detail, building a clear record of your hormone protocol over time.

Whether you're on patches, gels, oral tablets, or a combination, the app tracks your schedule and flags when doses are due. When your provider asks how your protocol has been going, you'll have a precise answer instead of a best guess.

Research & Clinical Evidence

The Basics

The body of research on dydrogesterone in HRT spans more than two decades of clinical trials and large-scale epidemiological studies. The most compelling findings relate to its effectiveness for vasomotor symptoms (hot flushes) and its safety profile compared to other progestogens.

Vasomotor symptoms. Multiple randomized controlled trials have tested the combination of estradiol with dydrogesterone at various doses. In a European multi-centre trial, the ultra-low dose combination (0.5 mg estradiol with 2.5 mg dydrogesterone) reduced moderate-to-severe hot flushes by 6.4 per day over 13 weeks, compared to 4.9 for placebo (p<0.001). This effect was comparable to a higher dose (1 mg/5 mg) [5]. A pooled analysis across European and Chinese populations confirmed this benefit is consistent across ethnicities [6].

Bone density. The Stevenson et al. systematic review found that estradiol/dydrogesterone combinations increased lumbar spine bone mineral density by 2.4% to 6.4% after two years, similar to other standard HRT regimens [7].

Breast cancer risk. The French E3N cohort study (80,377 postmenopausal women) found that the type of progestogen in combined HRT significantly influenced breast cancer risk. The relative risk was 1.16 (95% CI: 0.94-1.43) for estrogen combined with dydrogesterone, compared to 1.69 (1.50-1.91) for estrogen combined with other progestagens (MPA, norethisterone derivatives). This difference was not significant for dydrogesterone, meaning the study could not confirm an increased risk [8]. However, this does not prove absence of risk, and longer-term data remain limited.

VTE risk. A large UK study using the QResearch and CPRD databases (BMJ, 2019) found that among oral combined HRT formulations, estradiol with dydrogesterone carried the lowest VTE risk: an adjusted odds ratio of 1.18 (0.98-1.42), which was not statistically significant. By comparison, conjugated equine estrogens with MPA had the highest risk at 2.10 (1.92-2.31) [9].

The Science

Vasomotor Symptom Trials:
Three pivotal RCTs have established the vasomotor efficacy of E2/dydrogesterone:

1. European RCT (Gompel et al., 2010): 313 women randomized to E2 0.5/D 2.5 mg, E2 1/D 5 mg, or placebo. Primary endpoint: reduction in moderate-severe hot flushes/day at week 13. E2 0.5/D 2.5: -6.4 vs placebo -4.9 (p<0.001). E2 1/D 5: -6.3 (comparable). Amenorrhea rates at months 10-12: 91% for ultra-low dose [5].
2. Subgroup analysis (2020): Pooled efficacy from 2 RCTs confirmed treatment effect across subgroups defined by age (45-<55 and >=55), menopause duration, and BMI. No breast malignancies reported. Only one endometrial adverse event [10].
3. Multi-ethnic pooled analysis (2024): 579 women (European and Chinese) showed consistent improvements in VMS at weeks 4, 8, and end of treatment with E2 0.5/D 2.5 vs placebo, with positive impact on HRQoL [6].

E3N Breast Cancer Data:
The E3N cohort (Fournier et al., 2008; n=80,377) demonstrated differential breast cancer risk by progestogen type [8]:

• Estrogen + progesterone: RR 1.00 (0.83-1.22)
• Estrogen + dydrogesterone: RR 1.16 (0.94-1.43)
• Estrogen + other progestagens: RR 1.69 (1.50-1.91)

No significant difference by estrogen route (oral vs transdermal).

E3N Endometrial Cancer Data:
Fournier et al. (2014; n=65,630) found that estrogen + dydrogesterone was not associated overall with endometrial cancer risk (HR 1.05, 95% CI: 0.76-1.45). However, with long-term use (>5 years), risk increased (HR 1.69, 95% CI: 1.06-2.70). For context, estrogen + micronized progesterone also showed increased endometrial cancer risk with >5 years use (HR 2.66, 95% CI: 1.87-3.77) [11].

BMJ VTE Study (Vinogradova et al., 2019):
Nested case-control study using QResearch and CPRD databases [9]:

• Overall oral HRT vs no exposure: OR 1.58 (1.52-1.64)
• Oral estradiol + dydrogesterone: OR 1.18 (0.98-1.42), lowest among all oral combined formulations
• Oral CEE + MPA: OR 2.10 (1.92-2.31), highest risk
• Transdermal preparations: OR 0.93 (0.87-1.01), no significant increase
• Estradiol + dydrogesterone was associated with 44% lower VTE risk compared to CEE + MPA

60-Year Safety Profile (Ott et al., 2022):
Comprehensive review of dydrogesterone safety across all indications confirmed [2]:

• Breast cancer risk lower with dydrogesterone than with MPA, levonorgestrel, or norethisterone-containing MHT
• VTE and cardiovascular event risk low with dydrogesterone-containing regimens
• Does not reverse cardiovascular benefits of percutaneous estradiol
• Minimal adverse effects on breasts and endometrium with use up to 260 weeks

Evidence & Effectiveness Matrix

The following matrix uses the 20 HRT symptom/outcome categories. Evidence Strength is derived from clinical trial and epidemiological data. Reported Effectiveness incorporates community sentiment data where available.

Categories not scored (insufficient data): Sexual Function & Libido, Cognitive Function, Joint & Musculoskeletal Health, Skin Hair & Appearance, Energy & Fatigue, Headache & Migraine, Other Physical Symptoms.

Benefits & Therapeutic Effects

The Basics

Dydrogesterone's primary role is protecting the uterine lining when you take estrogen. In this protective function, it performs well: clinical trials show high amenorrhea rates (meaning no irregular bleeding) of up to 91% with continuous combined low-dose formulations [5]. For many women, avoiding unpredictable bleeding is a significant quality-of-life benefit.

Beyond endometrial protection, dydrogesterone offers some advantages that stem from what it does not do. Because it does not activate androgen receptors, it is less likely to cause acne, oily skin, or unwanted hair growth, side effects sometimes seen with progestogens derived from testosterone (like norethindrone). Because it does not oppose estradiol's beneficial effects on lipid profiles, some studies suggest it may help preserve the cardiovascular benefits of estrogen therapy [2][7].

The combination of estradiol and dydrogesterone has also been shown to improve bone mineral density, increase by 2.4 to 6.4% in the lumbar spine over two years, which is comparable to other established HRT regimens [7].

For women who cannot tolerate micronized progesterone (common reasons include severe drowsiness, mood disturbance, or gastrointestinal side effects), dydrogesterone offers an alternative progestogen option that many find better tolerated. Its lack of GABAergic activity means it does not cause the sedation associated with oral micronized progesterone [4].

The Science

The therapeutic benefits of dydrogesterone in MHT can be organized into direct progestogenic effects and indirect benefits from its neutral receptor profile:

Direct Progestogenic Benefits:

• Endometrial transformation and protection: adequate secretory transformation at 10 mg/day sequential or 2.5-5 mg/day continuous [1][7]
• High amenorrhea rates: 81% overall and 91% at months 10-12 with E2 0.5/D 2.5 continuous combined [5]
• Predictable bleeding patterns with sequential regimens

Benefits from Receptor Selectivity:

• Absence of androgenic activity preserves estradiol's SHBG-raising effect and avoids androgenic side effects [3]
• No glucocorticoid activity avoids potential negative metabolic effects (insulin resistance, visceral fat accumulation) seen with some synthetic progestins [2][7]
• Neutral to positive metabolic effects: Stevenson et al. review documented beneficial effects on lipid parameters, insulin sensitivity, glucose metabolism, and body fat distribution [7]
• Does not counteract cardiovascular benefits of percutaneous estradiol (Kuba et al.) [2]

Bone Protection:
Lumbar spine BMD increases of 2.4-6.4% after 2 years of E2/dydrogesterone combinations, comparable to other HRT regimens [7].

Risks, Side Effects & Safety

The Basics

Like all hormone therapies, taking dydrogesterone as part of combined HRT involves balancing benefits against risks. The evidence suggests that dydrogesterone may carry a more favorable risk profile than some other progestogens, but it is not risk-free.

Common side effects include headache, abdominal pain, breast tenderness, and back pain, which are the most frequently reported effects in clinical trials. Nausea, mood changes (including depression and nervousness), and weight changes can also occur [1]. Most of these side effects are mild and often improve within the first few months of treatment.

Breast cancer is understandably one of the most concerning risks with any combined HRT. The E3N cohort study, which followed over 80,000 postmenopausal women in France, found that estrogen combined with dydrogesterone did not show a statistically significant increase in breast cancer risk (relative risk 1.16, with the confidence interval crossing 1.0). By comparison, estrogen combined with other progestagens like MPA showed a clearly elevated risk of 1.69 [8]. To put the absolute numbers in perspective: among 1,000 women aged 50 who take combined E+P HRT for 5 years (using UK incidence data), approximately 8 additional cases of breast cancer would be expected compared to non-users. For dydrogesterone-containing combinations, the available evidence suggests this additional risk may be lower, though the data are not definitive.

Blood clots (VTE) are a recognized risk with oral HRT. A major UK study found that estradiol combined with dydrogesterone had the lowest VTE risk among all oral combined formulations studied: an odds ratio of 1.18, which was not statistically significant (meaning the study could not confirm a real increase) [9]. By comparison, conjugated equine estrogens combined with MPA had the highest risk at 2.10. In absolute terms, among 1,000 women aged 50-59 taking oral combined HRT for 5 years, approximately 5 additional VTE events would be expected over baseline [1]. For transdermal estrogen (patches or gel), no significant VTE increase has been documented regardless of which progestogen is used.

Endometrial safety is generally good at recommended doses, though the E3N study raised a question about very long-term use (beyond 5 years), where a modest increase in endometrial cancer risk was observed at the doses commonly used in France [11]. This finding requires context: the doses used in French clinical practice may have been lower than those recommended in the UK SmPC, and the Million Women Study found no increased endometrial cancer risk with combined HRT overall [1].

Stroke risk is modestly increased with all combined HRT (approximately 1.5-fold relative increase). In absolute terms, among 1,000 women aged 50-59, this corresponds to approximately 3 additional cases over 5 years [1].

Meningioma has been reported in association with dydrogesterone use and is listed as a contraindication in the current SmPC. If a patient is diagnosed with meningioma, dydrogesterone-containing treatment must be discontinued [1].

The Science

Common Adverse Events (from n=4,929 in clinical trials) [1]:

Breast Cancer Risk -- Absolute Risk Context:

Based on the largest available meta-analysis (UK incidence data, women with BMI 27, starting HRT at age 50) [1]:

The E3N data suggest that dydrogesterone-containing combinations may fall closer to the estrogen-only risk profile (RR 1.16) than to the overall combined HRT average (RR 1.6), though this comparison requires confirmation in additional large cohorts [8].

VTE Risk -- Absolute Numbers:

Risk Modifiers:

• Obesity (BMI >30): increases VTE risk independently
• Smoking: amplifies cardiovascular and VTE risk with oral HRT
• Family history of VTE or known thrombophilia: contraindication to HRT
• Prior VTE: absolute contraindication
• Age >60 or >10 years post-menopause: less favorable risk-benefit ratio for systemic HRT initiation

Contraindications [1]:

• Known or suspected breast cancer
• Known or suspected oestrogen-dependent malignant tumours
• Undiagnosed genital bleeding
• Untreated endometrial hyperplasia
• Previous or current VTE
• Known thrombophilic disorders
• Active or recent arterial thromboembolic disease
• Acute liver disease or abnormal liver function
• Porphyria
• Meningioma or history of meningioma

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're experiencing breakthrough bleeding, headaches, breast tenderness, or any other change, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also checks for interactions between your HRT and any other medications or supplements you're taking.

Dosing & Treatment Protocols

The Basics

Dydrogesterone is available in several dose combinations, and the right one depends on where you are in your menopause journey and what your provider recommends. There are two main approaches:

Sequential (cyclic) regimens are typically used in perimenopause or early postmenopause. You take estradiol every day of the cycle, and dydrogesterone is added for the last 14 days. This produces a regular withdrawal bleed each month, similar to a menstrual period. Common sequential options include Femoston 1/10 (1 mg estradiol + 10 mg dydrogesterone) and Femoston 2/10 (2 mg estradiol + 10 mg dydrogesterone) [1].

Continuous combined regimens are used in postmenopausal women (at least 12 months since their last natural period). You take both estradiol and dydrogesterone every day without a break. The goal is to avoid any bleeding. Options include Femoston-conti 0.5/2.5 (ultra-low dose) and Femoston-conti 1/5 [1]. The ultra-low dose combination aligns with current guidelines recommending the lowest effective dose.

Standalone dydrogesterone (Duphaston 10 mg or Nalvee 10 mg) can be prescribed alongside separate estrogen preparations (such as estradiol patches or gel). Common dosing for endometrial protection is 10 mg daily for 12-14 days per cycle (sequential) or 5-10 mg daily (continuous) [1][2].

The general principle in current clinical practice is to start with the lowest effective dose and adjust upward if symptoms are not adequately controlled. Tablets can be taken with or without food, and the timing is flexible, though consistency helps maintain stable blood levels.

The Science

Standard Dosing Regimens [1][7]:

Dose titration considerations:

• The lowest effective dose for the shortest duration should be used [1]
• Clinical response typically assessed at 4-12 weeks
• Dose escalation from ultra-low to low dose if symptom relief is inadequate
• Transition from sequential to continuous combined is appropriate once at least 12 months postmenopausal

Dose equivalence guidance:

• Dydrogesterone 10 mg sequential provides endometrial transformation equivalent to micronized progesterone 200 mg sequential [2][3]
• Dydrogesterone 2.5-5 mg continuous provides endometrial protection equivalent to micronized progesterone 100 mg continuous

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually taking, doses, timing, and any adjustments, makes that process smoother. Doserly tracks your HRT doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you took your morning dose or when you last changed your patch. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes hormone therapy most effective.

What to Expect (Timeline)

Days 1-7:
Initial adjustment period. Some women experience breast tenderness, mild nausea, or headache. If on a sequential regimen and starting the dydrogesterone phase, PMS-like symptoms (bloating, mood sensitivity) may occur during the first cycle. These effects are typically mild.

Weeks 2-4:
If taking a continuous combined formulation, breakthrough spotting is common in the first month and is not a cause for concern. Hot flushes typically begin to improve, with clinical trials showing statistically significant vasomotor improvement from week 4 [5]. Sleep and mood may begin to stabilize as estradiol levels reach steady state (approximately 5-8 days for estradiol, 3 days for dydrogesterone).

Months 1-3:
Vasomotor symptoms typically improve significantly. Initial side effects (breast tenderness, bloating) usually resolve. Bleeding patterns begin to settle, particularly with continuous combined regimens. Irregular spotting should decrease progressively.

Months 3-6:
Full therapeutic effect for vasomotor symptoms is typically established. With continuous combined Femoston-conti 0.5/2.5, amenorrhea rates increase: from 79-90% in months 1-3 to the 80-91% range by months 4-6 [5]. Bone density stabilization begins. Quality of life improvements are typically well-established. GSM improvements (from the estradiol component) become more apparent.

Ongoing Maintenance:
Annual review with your provider to reassess the benefit-risk balance. Dosing adjustments may be considered based on symptom response, side effects, and evolving risk profile. Mammography per national guidelines. Endometrial assessment if abnormal bleeding occurs. Amenorrhea rates with continuous combined regimens reach 91% by months 10-12 [1][5].

Individual response varies considerably. Some women notice improvements within days, while others require weeks or dose adjustments. Work with your provider to find the approach that works best for you.

Timing Hypothesis & Window of Opportunity

The timing hypothesis proposes that the balance of risks and benefits for systemic HRT is more favorable when treatment is initiated within 10 years of menopause onset or before age 60. This concept emerged from reanalysis of WHI data and has been supported by several subsequent studies.

Supporting evidence: The WHI age subgroup analyses showed that women aged 50-59 at enrollment had a more favorable cardiovascular profile on HRT than women aged 60-79 [12]. The KEEPS trial demonstrated that early-initiation HRT (within 3 years of menopause) in healthy women was associated with improvements in several cardiovascular surrogate markers without increased risk [13]. The ELITE trial provided direct evidence that timing matters: estradiol reduced carotid intima-media thickness progression in women within 6 years of menopause but not in those more than 10 years post-menopause [14].

Relevance to dydrogesterone: The timing hypothesis applies to the estrogen component of HRT rather than to the progestogen specifically. However, the choice of progestogen may influence the overall risk-benefit equation. Dydrogesterone's relatively neutral effects on metabolic and vascular parameters (compared to MPA, which attenuated estrogen's cardiovascular benefits in the WHI) may make it a particularly appropriate progestogen choice for women initiating HRT during the window of opportunity [2][7].

Limitations: No RCT has been specifically designed and powered to test the timing hypothesis definitively. The concept is supported by plausible biological mechanisms (the "healthy endothelium" hypothesis: estrogen protects healthy vascular endothelium but may destabilize pre-existing atherosclerotic plaques) and by consistent signals across multiple studies, but it remains evolving evidence rather than settled science.

Interactions & Compatibility

Drug-Drug Interactions:

• CYP3A4 inducers (rifampicin, phenobarbital, carbamazepine, phenytoin, efavirenz, nevirapine): May increase metabolism of dydrogesterone and estradiol, reducing efficacy. Dose adjustment or alternative progestogen delivery may be needed [1].
• Ritonavir, nelfinavir: Despite being CYP inhibitors, these agents have inducing properties when combined with steroid hormones [1].
• Lamotrigine: Estrogen-containing HRT may reduce lamotrigine levels through glucuronidation induction, potentially reducing seizure control. Monitor levels if co-administered [1].
• Thyroid medications: Estrogen increases thyroid-binding globulin (TBG), which may require levothyroxine dose adjustment. Free T4 and T3 are typically unaffected [1].
• Anticoagulants: Monitor INR/coagulation parameters when initiating or changing HRT in patients on warfarin.
• Hepatitis C treatments: Caution with ombitasvir/paritaprevir/ritonavir, dasabuvir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir. ALT elevations reported with ethinylestradiol; lower risk with estradiol but caution warranted [1].

Supplement Interactions:

• St. John's Wort (Hypericum perforatum): Induces CYP3A4 metabolism of both estrogens and progestogens. May reduce HRT efficacy. Avoid concurrent use or use with awareness of potential reduced hormone levels [1].
• Calcium and Vitamin D: No interaction; recommended complementary supplementation for bone health.
• Black cohosh: No known pharmacokinetic interaction with dydrogesterone. Sometimes used alongside HRT; discuss with provider.

Lifestyle Factors:

• Smoking: Dramatically increases VTE and cardiovascular risk with oral HRT. Current guidelines strongly advise against smoking while on HRT, and smokers may be better candidates for transdermal estrogen [1].
• Alcohol: Modest interaction with hepatic metabolism. Moderate consumption unlikely to significantly affect dydrogesterone efficacy.
• Grapefruit: CYP3A4 inhibitor; may modestly increase dydrogesterone and estradiol levels. Not typically clinically significant at normal dietary intake.

Cross-References:

• Micronized Progesterone (Prometrium) -- alternative progestogen option
• Medroxyprogesterone Acetate (Provera) -- commonly compared progestin
• Norethindrone Acetate (Aygestin) -- another synthetic progestogen alternative

Decision-Making Framework

Choosing a progestogen is one of several important decisions in HRT. This section provides a framework for informed discussion with your healthcare provider.

Candidate assessment for dydrogesterone:

• Women with an intact uterus who require progestogen protection alongside estrogen therapy
• Women who have not tolerated micronized progesterone (e.g., due to excessive sedation, mood disturbance, or GI effects)
• Women concerned about the androgenic side effect profile of 19-nortestosterone-derived progestins
• Women who prefer a fixed-dose combination product (Femoston range)
• Women in countries where dydrogesterone is available (not suitable for US-based patients)

Questions to discuss with your provider:

• "How does dydrogesterone compare to micronized progesterone for endometrial protection in my situation?"
• "Given the E3N data on breast cancer risk by progestogen type, is dydrogesterone an appropriate choice for my risk profile?"
• "Is a sequential or continuous combined regimen more appropriate for my stage of menopause?"
• "If I am currently on patches or gel for estrogen, can I add standalone dydrogesterone (Duphaston/Nalvee)?"
• "How should we monitor my endometrial health while on dydrogesterone, especially if I plan to use it for more than 5 years?"

Finding a menopause specialist:

• In the UK: British Menopause Society (BMS) maintains a list of accredited menopause specialists
• Internationally: IMS, EMAS, and national menopause societies offer provider directories
• In the US: dydrogesterone is not available; discuss alternatives such as micronized progesterone with a NAMS-certified menopause practitioner

Self-advocacy guidance:
If your provider is unfamiliar with dydrogesterone or dismisses your request to try it, consider asking for a referral to a menopause specialist. If you are struggling with side effects from your current progestogen, you have the right to explore alternatives. Bring evidence (such as the E3N study findings) to your appointment to support an informed conversation.

Administration & Practical Guide

Dydrogesterone is available only as an oral tablet. Administration is straightforward:

Standalone Duphaston/Nalvee (10 mg tablets):

• Scored tablets that can be halved if a lower dose is prescribed
• Take at the same time each day for consistency
• Can be taken with or without food
• If using sequentially, take for the last 12-14 days of each 28-day estrogen cycle

Femoston combination tablets:

• Sequential packs (1/10 or 2/10): Take the estradiol-only tablets for the first 14 days, then the combined estradiol/dydrogesterone tablets for the next 14 days. Start a new pack immediately after completing the previous one.
• Continuous combined packs (0.5/2.5 or 1/5): Take one tablet daily without interruption. Packs are taken continuously without breaks.

Missed dose guidance:

• If less than 12 hours since the missed dose: take it as soon as you remember
• If more than 12 hours have elapsed: skip the missed dose and take the next one at the usual time. The likelihood of breakthrough bleeding or spotting may increase [1].

Storage: No special storage requirements. Store at room temperature. Keep out of reach of children.

Important notes:

• This is a prescription medication. Never adjust dosing without consulting your prescriber.
• Dydrogesterone is not a contraceptive. If you are perimenopausal and still at risk of pregnancy, discuss contraception separately with your provider.
• If you are having surgery, inform your surgeon that you are taking HRT. Your provider may recommend temporarily stopping HRT 4-6 weeks before elective surgery to reduce VTE risk [1].

Monitoring & Lab Work

Pre-HRT Baseline:

• Complete personal and family medical history
• Physical examination including breast examination
• Mammography (per national screening guidelines)
• Blood pressure measurement
• Pelvic ultrasound (consider if history of abnormal bleeding or fibroids)
• Hormone levels (FSH, estradiol): helpful for confirming menopausal status, though not strictly required for women over 45 with typical symptoms
• Lipid panel, liver function tests, thyroid function
• DEXA scan if osteoporosis risk factors are present

Initial Follow-Up (4-12 weeks):

• Symptom assessment: are vasomotor symptoms improving?
• Side effect evaluation: breast tenderness, mood changes, bleeding patterns
• Blood pressure check
• Dose adjustment consideration if symptoms are not adequately controlled

Ongoing Monitoring:

• Annual provider review: reassess benefit-risk balance, discuss duration of therapy
• Mammography: per national guidelines (typically annually or biennially depending on jurisdiction)
• Endometrial monitoring: transvaginal ultrasound if abnormal bleeding occurs. Routine endometrial monitoring in asymptomatic women is not generally recommended.
• Lipid panel: periodically as per cardiovascular risk profile
• Liver function: primarily relevant if hepatic concerns arise
• Bone density (DEXA): baseline and follow-up per osteoporosis risk assessment
• Blood pressure: regular monitoring at each visit

Annual Review Checklist:

• Are you still experiencing symptoms that justify continuing HRT?
• Have any new risk factors developed (e.g., family history of breast cancer, VTE event, liver disease)?
• Are you experiencing any concerning side effects?
• Would a dose adjustment or formulation change be appropriate?
• Is mammography up to date?
• Should bone density be reassessed?

Complementary Approaches & Lifestyle

While dydrogesterone addresses the progestogenic component of HRT, overall menopause management benefits from complementary strategies:

Supplements:

• Vitamin D (1000-2000 IU/day): supports bone health and immune function. Deficiency is common in postmenopausal women. (Vitamin D guide)
• Calcium (1000-1200 mg/day, food + supplement): essential for bone health alongside HRT
• Magnesium (300-400 mg/day): may support sleep quality and muscle relaxation (Magnesium guide)
• Omega-3 fatty acids: may support cardiovascular health and reduce inflammation

Exercise:

• Weight-bearing exercise: walking, jogging, dancing, and stair climbing for bone health
• Resistance training: preserves lean muscle mass and supports metabolic health
• Cardiovascular exercise: supports heart health
• Balance training: reduces fall and fracture risk

Diet:

• Mediterranean diet pattern: associated with cardiovascular benefit and anti-inflammatory effects
• Phytoestrogen-rich foods (soy, flaxseed): modest evidence for mild vasomotor symptom relief
• Calcium-rich foods: dairy, leafy greens, fortified foods
• Limit alcohol and caffeine: may worsen vasomotor symptoms and sleep disruption

Mind-Body Approaches:

• CBT for vasomotor symptoms: NICE-recommended evidence-based approach
• Pelvic floor physiotherapy: for GSM and urinary symptoms
• Sleep hygiene: consistent schedule, cool bedroom, limit screens before bed
• Stress management: yoga, meditation, deep breathing exercises

Stopping HRT / Discontinuation

When to consider stopping:
There is no mandatory stop date for HRT. Current guidelines recommend annual reassessment of the benefit-risk balance rather than a fixed duration. Common reasons to consider stopping include resolution of menopausal symptoms, development of new risk factors (e.g., breast cancer diagnosis), or personal preference.

Tapering strategies:

• Gradual dose reduction over weeks to months is generally preferred over abrupt cessation
• Step-down approach: e.g., from Femoston-conti 1/5 to 0.5/2.5 for several months, then discontinue
• Some women transition from systemic HRT to vaginal-only estrogen for persistent GSM symptoms
• There is no consensus on the optimal tapering schedule; individualize based on symptom response

Symptom recurrence:
Approximately 50% of women experience some return of vasomotor symptoms after stopping HRT. The severity is typically similar to pre-treatment levels, not worse. Symptom recurrence is more likely in women who had severe symptoms before starting HRT. If symptoms recur and significantly affect quality of life, restarting HRT can be discussed with your provider.

What to monitor during discontinuation:

• Symptom diary: track hot flushes, sleep quality, mood during taper
• Bone density follow-up: particularly important if HRT was part of osteoporosis prevention
• Cardiovascular risk reassessment

Special Populations & Situations

Premature Ovarian Insufficiency (POI)

Women with POI (menopause before age 40) should receive HRT at least until the typical age of natural menopause (approximately 51). In this population, dydrogesterone/estradiol combinations such as Femoston 2/10 provide both hormone replacement and endometrial protection. The benefit-risk balance is strongly favorable in younger women because of the cardiovascular, bone, and cognitive protection that estrogen replacement provides [1].

Surgical Menopause

Women who undergo bilateral oophorectomy experience abrupt hormone loss and often require higher initial estrogen doses. Dydrogesterone can be used as the progestogen component if the uterus is intact. If the uterus was also removed (total hysterectomy with bilateral oophorectomy), no progestogen is needed.

Progestogen Intolerance

Dydrogesterone is frequently considered as an alternative for women who cannot tolerate micronized progesterone. The most common reasons for switching include excessive sedation (dydrogesterone lacks GABAergic metabolites), severe mood disturbance, or gastrointestinal side effects. Community reports support dydrogesterone as a viable alternative in many of these cases, though some women report mood sensitivity to dydrogesterone as well.

Migraine with Aura

Stable hormone levels are important for migraine sufferers. Continuous combined regimens (Femoston-conti) are generally preferred over sequential regimens to avoid cyclical hormone fluctuations. The choice of progestogen is less critical than the estrogen delivery route (transdermal preferred for migraine with aura to avoid oral estrogen's first-pass effects). If oral estrogen is used, the stable daily dosing of continuous combined Femoston-conti may be preferable.

Cardiovascular Disease History

Transdermal estrogen is generally preferred for women with cardiovascular risk factors. If oral administration is chosen, the lower VTE risk observed with estradiol + dydrogesterone (compared to CEE + MPA) may be relevant to the risk-benefit discussion [9].

Type 2 Diabetes

Dydrogesterone's neutral metabolic profile (no glucocorticoid activity, favorable effects on insulin sensitivity) may make it a suitable progestogen choice for women with type 2 diabetes, though direct clinical trial data in this population are limited [7].

Regulatory, Insurance & International

United States (FDA):
Dydrogesterone has never been submitted for FDA approval and is not available in the US market. American women do not have access to dydrogesterone-containing products through standard prescribing channels. Alternatives available in the US include micronized progesterone (Prometrium), medroxyprogesterone acetate (Provera), and norethindrone acetate.

United Kingdom (MHRA):
Dydrogesterone is widely available. The Femoston range (Exeltis UK Ltd) is one of the most commonly prescribed HRT products on the NHS. Nalvee 10 mg (Gedeon Richter) is a standalone dydrogesterone product recently made available. HRT is subject to NHS prescription charges, though the HRT prepayment certificate allows women to pay a fixed annual fee for all HRT prescriptions.

European Union (EMA):
Approved through national authorizations across EU member states. Duphaston and Femoston are widely available. The specific product range varies by country.

Australia (TGA):
Femoston range and Duphaston are registered and available. Listed on the Pharmaceutical Benefits Scheme (PBS) with applicable co-payments.

Canada (Health Canada):
Limited availability. Not as widely prescribed as in Europe or Australia.

International:
Dydrogesterone is approved and used in over 100 countries, including extensive use across Asia (India, China, Southeast Asia), the Middle East, and Latin America. It is one of the most widely prescribed progestogens globally, despite its absence from the US market.

Frequently Asked Questions

Is dydrogesterone the same as progesterone?
No. Dydrogesterone is a synthetic progestogen that is structurally very similar to natural progesterone but is not identical. It is a stereoisomer (mirror image) with additional modifications that give it higher oral bioavailability and selective receptor binding. Unlike "bioidentical" micronized progesterone, dydrogesterone is classified as a synthetic progestin, though its receptor profile is closer to natural progesterone than most other synthetic progestins.

Is dydrogesterone available in the United States?
No. Dydrogesterone has never been approved by the FDA and is not available through US pharmacies. Women in the US who seek a progestogen with a favorable safety profile are typically prescribed micronized progesterone (Prometrium).

Is dydrogesterone safer than MPA (Provera) for breast cancer risk?
The E3N cohort study suggests that dydrogesterone is associated with a lower breast cancer risk than MPA and other synthetic progestins when combined with estrogen. However, "lower risk" is not "no risk," and the evidence is observational rather than from randomized trials. Discuss your individual risk profile with your provider.

Does dydrogesterone help with sleep like micronized progesterone does?
Probably not to the same degree. Micronized progesterone produces a metabolite (allopregnanolone) that acts on GABA receptors in the brain, producing a sedative effect that many women find helpful for sleep. Dydrogesterone does not produce this metabolite. Some women report mild sleep improvement, but the pronounced sleep benefit of micronized progesterone is not expected with dydrogesterone.

Can I take dydrogesterone with estrogen patches or gel?
Yes. Standalone dydrogesterone (Duphaston or Nalvee) can be prescribed alongside any estrogen preparation, including transdermal patches, gel, or spray. This combination allows you to benefit from the lower VTE risk of transdermal estrogen while using dydrogesterone for endometrial protection.

What if I experience mood changes on dydrogesterone?
Some women report depression, anxiety, or mood sensitivity on dydrogesterone, particularly during the progestogen phase of sequential regimens. If this occurs, discuss with your provider. Options include switching to micronized progesterone (which some women tolerate better for mood), adjusting the dose, trying vaginal administration of micronized progesterone, or considering a Mirena IUD for endometrial protection.

How long can I take dydrogesterone?
There is no fixed maximum duration. Current guidelines recommend annual reassessment of the benefit-risk balance. The E3N study noted that long-term use (>5 years) at certain dose levels may be associated with modestly increased endometrial risk, which underscores the importance of regular monitoring and the use of adequate doses.

Is dydrogesterone a "bioidentical" hormone?
No, not in the strict pharmacological sense. "Bioidentical" typically refers to hormones that are molecularly identical to endogenous hormones. Dydrogesterone is a modified version of progesterone (a retroprogesterone) with an altered spatial configuration. However, its receptor binding profile is very similar to natural progesterone, and it is sometimes informally described as "close to bioidentical." Micronized progesterone is the only truly bioidentical progestogen.

Will I have periods on dydrogesterone?
It depends on the regimen. Sequential Femoston (1/10 or 2/10) produces a regular monthly withdrawal bleed. Continuous combined Femoston-conti is designed to be bleed-free, with amenorrhea rates of 81-91% at months 10-12. Breakthrough spotting may occur in the first 3-6 months of continuous combined therapy.

What should I do if I develop breakthrough bleeding?
Spotting in the first 3-6 months of continuous combined therapy is common and usually resolves. If bleeding persists beyond 6 months, starts after a period of amenorrhea, or is heavy, contact your provider. Further investigation (such as transvaginal ultrasound or endometrial biopsy) may be needed to rule out endometrial pathology.

Myth vs. Fact

Myth: Dydrogesterone is "natural" because it comes from progesterone.
Fact: Dydrogesterone is a synthetic progestogen. While its molecular structure is derived from progesterone and its receptor binding profile is similar, it is not molecularly identical to endogenous progesterone. Micronized progesterone (Prometrium/Utrogestan) is the only progestogen that is structurally identical to what your ovaries produce. However, "synthetic" does not automatically mean "less safe." The E3N cohort data suggest dydrogesterone has a breast cancer risk profile similar to micronized progesterone and substantially better than other synthetic progestins [8].

Myth: All synthetic progestins carry the same breast cancer risk.
Fact: The E3N cohort study (80,377 women) demonstrated significant differences in breast cancer risk by progestogen type. Estrogen + dydrogesterone: RR 1.16 (not significant). Estrogen + other synthetic progestagens (MPA, norethisterone derivatives): RR 1.69 (significant). Estrogen + micronized progesterone: RR 1.00 (not significant) [8]. The type of progestogen matters.

Myth: Dydrogesterone has the same blood clot risk as all oral HRT.
Fact: A major UK study (BMJ, 2019) found that estradiol + dydrogesterone had the lowest VTE risk among all oral combined HRT formulations: OR 1.18 (non-significant), compared to CEE + MPA at OR 2.10 [9]. While oral HRT generally carries higher VTE risk than transdermal, not all oral formulations are equal.

Myth: You must stop HRT after 5 years.
Fact: The "5-year rule" is outdated. Current guidelines from the Menopause Society, NICE, IMS, and BMS recommend individualized duration assessment based on ongoing symptom evaluation and risk-benefit analysis, reviewed annually. Some women benefit from continuing HRT well beyond 5 years, particularly those with POI or persistent symptoms [12].

Myth: If you can tolerate micronized progesterone, there's no reason to use dydrogesterone.
Fact: For many women, micronized progesterone is an excellent choice and the first-line recommendation in many guidelines. However, dydrogesterone offers specific advantages for some: it does not cause the sedation associated with micronized progesterone's GABAergic metabolites, it has a more convenient dosing range (lower pill burden), and it is available in fixed-dose combinations with estradiol (Femoston) that simplify daily regimens.

Myth: Dydrogesterone provides the same sleep benefit as micronized progesterone.
Fact: Micronized progesterone produces allopregnanolone, a metabolite that acts on brain GABA receptors and promotes sleep. This is a specific pharmacological property of micronized progesterone that dydrogesterone does not share. If sleep improvement is a priority, micronized progesterone taken at bedtime may be more appropriate [4].

Myth: Compounded hormones are always better than manufactured products like Femoston.
Fact: Compounded HRT products are not subject to the same quality control, batch consistency, or regulatory oversight as manufactured products. The Femoston range has undergone extensive clinical testing, with documented efficacy and safety data from multiple RCTs and a well-characterized pharmacokinetic profile. Compounding may be appropriate when a specific dose or formulation is genuinely unavailable, but it should not be assumed superior to regulated products [15].

Myth: HRT causes breast cancer.
Fact: This is an oversimplification of complex data. Combined estrogen + progestogen HRT is associated with a modest increase in breast cancer risk that depends on the type of progestogen, duration of use, and individual risk factors. Using UK incidence data: among 1,000 women aged 50 taking combined HRT for 5 years, approximately 8 additional breast cancer cases would be expected over the baseline rate. For context, the additional risk from combined HRT is comparable to the additional risk associated with regular alcohol consumption (2-3 units/day) or obesity [1][8].

Sources & References

Clinical Guidelines

[1] Exeltis Healthcare. Femoston-conti 0.5 mg/2.5 mg Film-coated Tablets. Summary of Product Characteristics (SmPC). Electronic Medicines Compendium (EMC). Updated May 2025. https://www.medicines.org.uk/emc/product/2825/smpc

[12] The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause. 2022;29(7):767-794.

[15] ACOG Committee Opinion No. 789: Compounded Bioidentical Menopausal Hormone Therapy. Obstet Gynecol. 2019;134(4):e106-e112.

Systematic Reviews & Meta-Analyses

[7] Stevenson JC, Panay N, Pexman-Fieth C. Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety. Maturitas. 2013;76(2):208-214. PMID: 23835005.

[2] Ott J et al. Dydrogesterone after 60 years: a glance at the safety profile. Gynecol Endocrinol. 2022;38(4):279-287.

Pharmacological Studies

[3] Rizner TL, Brozic P, Doucette C, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607-615.

[4] Griesinger G, Tournaye H, Macklon N, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249-259. PMID: 30595525.

Randomized Controlled Trials

[5] Gompel A, et al. Oral ultra-low dose continuous combined HRT with 0.5 mg 17-beta-oestradiol and 2.5 mg dydrogesterone for treatment of vasomotor symptoms. Maturitas. 2010;67(3):227-232. PMID: 20688442.

[6] Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms. Post hoc analysis of two phase 3 studies. PMID: 39077780.

[10] Efficacy and safety of a low-dose continuous combined HRT with 0.5 mg 17-beta-estradiol and 2.5 mg dydrogesterone. Subgroup analysis. PMID: 32747036.

Observational Studies

[8] Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103-111. PMID: 17333341.

[9] Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810.

[11] Fournier A, Dossus L, Mesrine S, et al. Risks of endometrial cancer associated with different hormone replacement therapies in the E3N cohort, 1992-2008. Am J Epidemiol. 2014;180(5):508-517.

Landmark Trials (Referenced for Context)

[13] Harman SM, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial (KEEPS). Ann Intern Med. 2014;161(4):249-260.

[14] Hodis HN, et al. Vascular effects of early versus late postmenopausal treatment with estradiol (ELITE). N Engl J Med. 2016;374(13):1221-1231.

Related Guides & Cross-Links

Same Category (Progestogens)

• Micronized Progesterone (Prometrium)
• Medroxyprogesterone Acetate (Provera)
• Norethindrone Acetate (Aygestin)
• Drospirenone
• Levonorgestrel (Mirena IUD)
• Nomegestrol Acetate

Related Treatment Options

• 17B-Estradiol (Bioidentical) -- commonly paired estrogen
• Estradiol + Progesterone (Bijuva) -- alternative combined product
• Estradiol + Drospirenone (Angeliq) -- alternative combined product
• Getting Started with HRT -- overview guide

Complementary Approaches

• Vitamin D -- bone health support
• Magnesium -- sleep and muscle support
• Calcium -- bone health support

Conditions & Stages

• Menopause
• Perimenopause
• Premature Ovarian Insufficiency
• Surgical Menopause